Biogen Inc (BUE:BIIB)
ARS 18636 201.5 (1.09%) Market Cap: 28.98 Til Enterprise Value: 34.17 Til PE Ratio: 28.13 PB Ratio: 2.14 GF Score: 49/100

Biogen Inc Aducanumab Phase 3 Topline Results at AAIC (encore presentation and Q&A) Transcript

Jul 29, 2020 / 12:00PM GMT
Release Date Price: ARS2500 (-1.96%)
Francesca Cormack;University of Cambridge
Cambridge, United Kingdom,

Olivia, would you like to introduce?

Olivia Hampton;Massachusetts General Hospital
Harvard Medical School, Boston, MA, USA,

Yes. So next, we will hear from the Biogen Group. The presenter will be Dr. Samantha Budd Haeberlein, and Dr. Carmen Castrillo will be available for Q&A afterwards. And they will be presenting on EMERGE and ENGAGE top line results, Phase III studies of aducanumab in early Alzheimer's disease.

Samantha Budd Haeberlein
Biogen Inc. - VP of Clinical Development

I'm going to present top line results from EMERGE and ENGAGE: Two Phase III Studies to Evaluate Aducanumab in Patients with Early Alzheimer's Disease.

Aducanumab is an investigational compound and is not yet approved in any country. The aducanumab Phase III studies, EMERGE and ENGAGE, were 2 18-month randomized, double-blind, placebo-controlled Phase III studies. We randomized 3,285 patients at 348 sites. Patients had

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot